<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2B944851-7705-4F79-819D-F8B04312F6F2"><gtr:id>2B944851-7705-4F79-819D-F8B04312F6F2</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Nunn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A4206479-8080-4D3A-AD65-18A0DE4B3549"><gtr:id>A4206479-8080-4D3A-AD65-18A0DE4B3549</gtr:id><gtr:firstName>Angela</gtr:firstName><gtr:surname>Crook</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122888468"><gtr:id>1FFF9315-6B84-46EC-895B-5594F351F195</gtr:id><gtr:title>Respiratory Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122888468</gtr:grantReference><gtr:abstractText>Respiratory disease is responsible for a very considerable amount of morbidity and mortality within the UK but in recent years few clinical trials have been conducted apart from those assessing the treatment of lung cancer. The MRC Clinical Trials Unit and the Respiratory Trials Unit at Churchill Hospital in Oxford are involved in a programme of studies in pleural diseases and sleep disorders. The pleural cavity is the space between the lung and the chest wall which in certain diseases accumulates fluid which needs to be drained. Pleural effusions may have several possible causes, in particular infection or malignancy. A series of multi-centre trials are addressing the question how can this effusion be most effectively treated and drained.||Sleep disorders are common within the adult population and can result in severe tiredness during daytime leading to inability to work effectively and sometimes result in serious accidents. The most advanced cases of sleep apnoea are most effectively managed by the patient wearing a mask to assist breathing at night. It is uncertain whether similar benefits can be obtained in those with moderate sleep apnoea. One of the trials in the collaboration is assessing that together with the potential for the mask to reduce the risk of cardiovascular disease.</gtr:abstractText><gtr:technicalSummary>The CTU has been collaborating with the Respiratory Trials Unit (RTU) at the Churchill Hospital, Oxford over a number of years in the conduct of multi-centre trials. The main focus of the research programme is in pleural disease and sleep disorders. Although in the past the British Thoracic Society was active in multi-centre trials in respiratory disease in recent years there was been very limited funding and little activity in this area apart from trials in lung cancer. The current initiative began with a trial, MIST1, which assessed the role of streptokinase in pulmonary empyema; this was funded by the MRC and was a collaboration between the RTU in Oxford and the Clinical Trials Unit. The unexpected findings from that multi-centre trial has had considerable influence over the management of that condition and led to further trials and has provided important information on the nature of the pathogens involved in this disease and the corresponding differences in outcomes. A second trial assessing whether DNase or Alteplase, improve pleural fluid drainage in pleural infection, (MIST2) was recently completed A further series of trials in pleural disease is focussed on patients with malignant pleural effusions. These trials (TIME1 and TIME2) are addressing problems associated with pleurodesis (preventing re-accumulation of fluid), in particular the most optimum form of drainage and the analgesic most likely to minimise the associated pain. Smaller drains may be less painful but may not be as effective. TIME3 is addressing the role of fibrinolytics in reducing breathlessness.||Sleep disorders affect around 4% of the adult male population. Poor quality sleep associated with frequent waking through the night can lead to sever daytime symptoms which inhibit the ability to work effectively and may lead to accidents, particularly in drivers. For patients with severe obstructive sleep apnoea trials have shown the most effective treatment to be nasal CPAP which enables the patient to have a good nights sleep. The role of CPAP in those with moderate sleep apnoea is less clear, however there may be benefits in terms of reduction in risk factors for cardiovascular disease since CPAP reduces blood pressure while sleeping. The MOSAIC trial assesses whether there is benefit in sleepiness reduction in patients with moderate apnoea and whether their risk factor scores, as measured by the Framingham index, can be reduced. The PREDICT trial is assessing whether older patients could benefit from CPAP.|</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>445580</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC/Cancer Research UK/BHF Clinical Trial Service Unit &amp; Epidemiological Studies Unit</gtr:department><gtr:description>Oxford Respiratory Trials Unit (ORTU)</gtr:description><gtr:id>EEE92B7E-9B43-4B1D-9E20-A18797FE6D00</gtr:id><gtr:impact>Changes to guidelines</gtr:impact><gtr:outcomeId>121881EBC31-1</gtr:outcomeId><gtr:piContribution>This is an ongoing collaboration which has resulted in the ORTU receiving provisional regsitartion as an accredited trials unit by UKCRN and in the conduct of a number of trials in respiratory medicine.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Treatment of pleural disease</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>3271FCDE-1FB5-4A65-9270-2B78A8C8434B</gtr:id><gtr:impact>The results of our collaborative trials on pleural infection have significantly changed the treatment of this disease by defining the clinical use of intrapleural adjuvant drainage therapies. These results are being included in clinical care guidelines for the treatment of pleural disease generated by the British Thoracic Society. These guidelines are in late peer review and are expected to be published in 2010.</gtr:impact><gtr:outcomeId>466567A278A</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>ACFBDBC6-65E3-4AF2-9FFE-919DAF8CE41C</gtr:id><gtr:title>Atherosclerosis and arterial stiffness in obstructive sleep apnea--a cardiovascular magnetic resonance study.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89e8bec628c3f05823924d53ef5d4a70"><gtr:id>89e8bec628c3f05823924d53ef5d4a70</gtr:id><gtr:otherNames>Kylintireas I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>5461ef7a13dd42.31581459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68C43419-1398-4ABB-917A-1406EA9A21F5</gtr:id><gtr:title>A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a78f61c194983d628228b936087a1577"><gtr:id>a78f61c194983d628228b936087a1577</gtr:id><gtr:otherNames>Rahman NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>5460ddd41df5b8.74843809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56232E66-08A8-4444-A0EB-F050D62A9776</gtr:id><gtr:title>Cardiovascular event rates in the MOSAIC trial: 2-year follow-up data.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d0e8d7b911e7998bf14ba4db9859949"><gtr:id>4d0e8d7b911e7998bf14ba4db9859949</gtr:id><gtr:otherNames>Turnbull CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5461ef7993f2c9.53669754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38B9865C-B727-439C-BB78-CDBD07EC2D84</gtr:id><gtr:title>A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/360e88c87fe0a6aabe04c75f2b1f7322"><gtr:id>360e88c87fe0a6aabe04c75f2b1f7322</gtr:id><gtr:otherNames>Khor CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>AD3CA25EBAB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F04D98BC-20B5-40F0-9B3E-CDFE07F2D57A</gtr:id><gtr:title>Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83ba0b54ae341fa7ab77ba270097e9ba"><gtr:id>83ba0b54ae341fa7ab77ba270097e9ba</gtr:id><gtr:otherNames>Chapman SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>77107834C82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B089010-361A-47FC-9F38-ACA0FBD8A675</gtr:id><gtr:title>Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a78f61c194983d628228b936087a1577"><gtr:id>a78f61c194983d628228b936087a1577</gtr:id><gtr:otherNames>Rahman NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>56b9f5ed1d3c66.81180889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A278151-8855-4269-A64C-51904EDA456D</gtr:id><gtr:title>CPAP improves endothelial function in patients with minimally symptomatic OSA: results from a subset study of the MOSAIC trial.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdeeeab76d1013f88e2ec23113ed039f"><gtr:id>cdeeeab76d1013f88e2ec23113ed039f</gtr:id><gtr:otherNames>Kohler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>5460de746ce3a9.80545505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74C476F2-43E1-40CD-A719-96B38234661C</gtr:id><gtr:title>U.K. Controlled trial of intrapleural streptokinase for pleural infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c34c4080eb158578bc11f3baa34477"><gtr:id>d6c34c4080eb158578bc11f3baa34477</gtr:id><gtr:otherNames>Maskell NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_14424_14_15745977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAE4C9DE-F04E-445F-BEB0-7BDE12963FDD</gtr:id><gtr:title>Circulating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoea.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/add394dd40d4ca161504d8f550b3e32c"><gtr:id>add394dd40d4ca161504d8f550b3e32c</gtr:id><gtr:otherNames>Ayers L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>5461ef79df9bc0.42821720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88AF21E1-E9A2-4625-92D7-E47A64DF5230</gtr:id><gtr:title>The bacteriology of pleural infection by genetic and standard methods and its mortality significance.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c34c4080eb158578bc11f3baa34477"><gtr:id>d6c34c4080eb158578bc11f3baa34477</gtr:id><gtr:otherNames>Maskell NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>071EE2F2D1C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13B4167D-3494-4DAD-BF63-B1781612ACAF</gtr:id><gtr:title>Leukoaraiosis on MRI in patients with minimally symptomatic obstructive sleep apnoea.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90836a4c73dcbfa1fbfdddb87dc5d2f5"><gtr:id>90836a4c73dcbfa1fbfdddb87dc5d2f5</gtr:id><gtr:otherNames>Schulz UG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>5461ef79b871f9.37568816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0553931-1263-4B39-A688-CE671BE42D6F</gtr:id><gtr:title>Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdfacf4a3a278cbd126f673b7439f88e"><gtr:id>cdfacf4a3a278cbd126f673b7439f88e</gtr:id><gtr:otherNames>Stradling JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5460d41614d807.92870243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94FB2E3D-AA0A-4098-9B09-7268FCA74C4A</gtr:id><gtr:title>Intrapleural use of tissue plasminogen activator and DNase in pleural infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a78f61c194983d628228b936087a1577"><gtr:id>a78f61c194983d628228b936087a1577</gtr:id><gtr:otherNames>Rahman NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>tvGFLQcSzai</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9879323A-0C45-4BD3-AD65-D1950CC46851</gtr:id><gtr:title>Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8a854b15d222632f64221d2afe25460"><gtr:id>e8a854b15d222632f64221d2afe25460</gtr:id><gtr:otherNames>Mishra EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a93d8360677e9.16996621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC89DD55-3889-4041-9849-35A2109A212A</gtr:id><gtr:title>Effect of CPAP on Cardiac Function in Minimally Symptomatic Patients with OSA: Results from a Subset of the MOSAIC Randomized Trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c71b9ea5254ce9e6bdd512e504bb52ce"><gtr:id>c71b9ea5254ce9e6bdd512e504bb52ce</gtr:id><gtr:otherNames>Craig S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1550-9389</gtr:issn><gtr:outcomeId>56b9f6c6ad7c57.41043755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7914248C-FE36-4C09-89DE-95859D3CFF77</gtr:id><gtr:title>IkappaB genetic polymorphisms and invasive pneumococcal disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83ba0b54ae341fa7ab77ba270097e9ba"><gtr:id>83ba0b54ae341fa7ab77ba270097e9ba</gtr:id><gtr:otherNames>Chapman SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>DB1B53AC6FF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E18EA762-C25B-4A83-B347-9E29563B2F2E</gtr:id><gtr:title>PTPN22 and invasive bacterial disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83ba0b54ae341fa7ab77ba270097e9ba"><gtr:id>83ba0b54ae341fa7ab77ba270097e9ba</gtr:id><gtr:otherNames>Chapman SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>DCEF4BAB75B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7DF331-451C-4B7F-B654-849260F3518E</gtr:id><gtr:title>Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d120e5430eded68abf61f6249e58f36"><gtr:id>0d120e5430eded68abf61f6249e58f36</gtr:id><gtr:otherNames>McMillan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5460dcffa92666.04189763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7639E5D-D6BF-4476-AC88-7E4EDE87378F</gtr:id><gtr:title>Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f57b913c43ce2c85c5d3eacf31b9a337"><gtr:id>f57b913c43ce2c85c5d3eacf31b9a337</gtr:id><gtr:otherNames>Davies HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>CEF113F5B32</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0DB2430-2BC2-49FD-B98F-F4C81BEB1A16</gtr:id><gtr:title>The relationship between chest tube size and clinical outcome in pleural infection.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a78f61c194983d628228b936087a1577"><gtr:id>a78f61c194983d628228b936087a1577</gtr:id><gtr:otherNames>Rahman NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>bbPyq6wYUr6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122888468</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>4CFCFE99-281F-452D-9C77-757ECDBEB0DC</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.3  Medical devices</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>